33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
    Meeting Abstract

    Baselga, J.; Dent, S. F.; Cortés, J.; Im, Y. H.; Diéras, V.; Harbeck, N.; Krop, I. E.; Verma, S.; Wilson, T. R.; Jin, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Diagnosis of mesothelioma based on cytology alone
    Meeting Abstract

    Sauter, J.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • From radiation oncology perspective
    Meeting Abstract

    Rimner, A.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Pan-cancer microsatellite instability to predict for presence of Lynch syndrome
    Meeting Abstract

    Latham Schwark, A.; Srinivasan, P.; Kemel, Y.; Shia, J.; Bandlamudi, C.; Mandelker, D.; Dubard-Gault, M.; Tran, C.; Middha, S.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma
    Meeting Abstract

    Slingluff, C. L.; Zarour, H. M.; Postow, M. A.; Friedlander, P. A.; Devoe, C. E.; Smith, K.; Deacon, D.; Macri, M. J.; Ryan, A.; Venhaus, R. R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer
    Meeting Abstract

    Soliman, H. H.; Robson, M. E.; Wagner, S.; Flake, D. D.; Schwartzberg, L. S.; Sharma, P.; Magliocco, A. M.; Kronenwett, R.; Lancaster, J. M.; Lanchbury, J. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Initial results of a dose escalation study of a selective and structurally differentiated PI3Kδ inhibitor, ME-401, in relapsed/refractory (R/R) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
    Meeting Abstract

    Soumerai, J. D.; Pagel, J. M.; Jagadeesh, D.; Salman, H. S.; Kenkre, V. P.; Asch, A. S.; Stathis, A.; Reddy, N. M.; Iasonos, A.; Ghalie, R.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation
    Meeting Abstract

    Stein, E.; Dinardo, C. D.; Jang, J. H.; Miyazaki, Y.; Martinez, R. O.; Auer, J.; Zhang, V.; Koralek, D. O.; Wu, B.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Ambulatory cancer care electronic symptom self-reporting (ACCESS) for surgical patients: A randomized controlled trial
    Meeting Abstract

    Stabile, C.; Temple, L. K. F.; Simon, B. A.; Stetson, P. D.; Stein, D.; Vickers, A. J.; Pusic, A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL
    Meeting Abstract

    Sehn, L. H.; Kamdar, M.; Herrera, A. F.; McMillan, A.; Flowers, C.; Kim, W. S.; Kim, T. M.; Özcan, M.; Demeter, J.; Hertzberg, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save